Our approach enables the use of this context both for the bioactivity model and the modeler. This work does highlight the importance of bioactivity data to be accompanied by well-annotated assay descriptions. Continued efforts should be made to make these descriptions available in a standardized format. Furthermore, follow-up work can likely further improve the handling of free text assay descriptions and therefore of large bioactivity datasets.